Next issueIssue 23 · Tue 17 Nov 

Trials

2026-525480-41-00

Trial ID
T-ctis-2026-525480-41-00
Registry
EU Clinical Trials Information System
NCT number
NCT07759245
CTIS number
2026-525480-41-00
Sponsor, as registered
Eli Lilly & Co.
Phase
Therapeutic exploratory (Phase II)
Indication
Pulmonary Disease, Chronic Obstructive
Status
Authorised
Start date
17/09/2026
Primary completion
CTIS does not publish one.
Member states concerned
Austria, Czechia, Germany, Denmark, France, Hungary, Poland, Romania
Sites
48

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-11-07

Notes on the record

Supersedes the row verified 2026-10-26 (kept), per DATA LAYER rule 4. Read from the CTIS public API retrieve endpoint 2026-11-07 (https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-525480-41-00; response sha256 498935ffac43). primary_completion_date is EMPTY because CTIS does not publish one. Per-state authorisation is NOT recorded and status codes are recorded verbatim, not decoded: the registry publishes no key. Brenipatide, Phase 2 (J2S-MC-GZMV). France mscPublicStatusCode 3 to 4 (collector, 6 Nov); on this read France 4, Romania 4, Czechia 4, Poland 4, Hungary 4, Germany 4, Denmark 2, Austria 2; member states unchanged (AT, CZ, DE, DK, FR, HU, PL, RO).

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting 2026-525480-41-00 in their own text.

Record history